2018
Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas
Lu E, Perlewitz KS, Hayden JB, Hung AY, Doung YC, Davis LE, Mansoor A, Vetto JT, Billingsley KG, Kaempf A, Park B, Ryan CW. Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas. Annals Of Surgical Oncology 2018, 25: 920-927. PMID: 29388122, DOI: 10.1245/s10434-018-6346-4.Peer-Reviewed Original ResearchConceptsSoft tissue sarcomasHigh-risk soft tissue sarcomasPhase II studyII studyPreoperative radiationTissue sarcomasHigh-grade soft tissue sarcomasHigh-risk STS patientsDistant disease-free survivalM2/dayExtensive institutional experienceLocal-regional failureDisease-free survivalRetrospective chart reviewDose-intense chemotherapyFavorable clinical outcomePercent of tumorsGy of radiationPostoperative cyclesTrimodality therapyPreoperative therapyWound complicationsChart reviewOverall survivalPathologic response
2011
Safety and efficacy of preoperative right portal vein embolization in patients at risk for postoperative liver failure following major right hepatectomy
Massimino K, Kolbeck K, Enestvedt C, Orloff S, Billingsley K. Safety and efficacy of preoperative right portal vein embolization in patients at risk for postoperative liver failure following major right hepatectomy. Hepato Pancreato Biliary 2011, 14: 14-19. PMID: 22151446, PMCID: PMC3252986, DOI: 10.1111/j.1477-2574.2011.00402.x.Peer-Reviewed Original ResearchConceptsRight portal vein embolizationPortal vein embolizationFuture liver remnantShort-term outcomesFLR volumeVein embolizationPreoperative right portal vein embolizationMajor right hepatectomyPost-embolization complicationsPostoperative liver failureRecords of patientsResults of embolizationDegree of hypertrophyHypertrophy rateRight hepatectomyLiver resectionMost complicationsOperative complicationsOperative resectionPatient demographicsComplication rateLiver failureLiver insufficiencyOperative outcomesLiver remnantPredicting malignant intraductal papillary mucinous neoplasm: a single-center review
Cone M, Rea J, Diggs B, Douthit M, Billingsley K, Sheppard B. Predicting malignant intraductal papillary mucinous neoplasm: a single-center review. The American Journal Of Surgery 2011, 201: 575-579. PMID: 21545902, DOI: 10.1016/j.amjsurg.2011.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, MucinousAdultAgedAged, 80 and overCarcinoma, Pancreatic DuctalCarcinoma, PapillaryDiagnosis, DifferentialEndosonographyFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedPancreatectomyPancreatic NeoplasmsPrognosisRetrospective StudiesSurvival RateTime FactorsTomography, X-Ray ComputedUnited StatesConceptsIntraductal papillary mucinous neoplasmInternational consensus guidelinesMalignant intraductal papillary mucinous neoplasmPapillary mucinous neoplasmConsensus guidelinesMucinous neoplasmsInvasive cancerMain duct intraductal papillary mucinous neoplasmPancreatic intraductal papillary mucinous neoplasmsPercent of patientsSingle-center reviewHigh-grade dysplasiaMayo criteriaWorse survivalPatient groupFemale sexSingle institutionMayo ClinicLower riskPatientsMultivariate analysisCancerResectionMain ductNeoplasmsOutcome After Laparoscopic Radiofrequency Ablation of Technically Resectable Colorectal Liver Metastases
Hammill C, Billingsley K, Cassera M, Wolf R, Ujiki M, Hansen P. Outcome After Laparoscopic Radiofrequency Ablation of Technically Resectable Colorectal Liver Metastases. Annals Of Surgical Oncology 2011, 18: 1947-1954. PMID: 21399885, DOI: 10.1245/s10434-010-1535-9.Peer-Reviewed Original ResearchMeSH KeywordsAgedCatheter AblationCohort StudiesColorectal NeoplasmsCombined Modality TherapyFemaleFollow-Up StudiesHumansLaparoscopyLiver NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPreoperative CareProspective StudiesRetrospective StudiesSurvival RateTomography, X-Ray ComputedTreatment OutcomeConceptsColorectal liver metastasesLaparoscopic radiofrequency ablationResectable colorectal liver metastasesRadiofrequency ablationResectable groupHepatic resectionLiver metastasesUnresectable groupMedian disease-free survivalComparable long-term survivalOutcomes of patientsDisease-free survivalKaplan-Meier methodLog-rank testLong-term survivalDiagnostic imaging studiesFavorable morbidityCRLM patientsPostoperative mortalityUnresectable diseaseMajor complicationsTumor numberResultsA totalSurgical oncologistsOutcome data
2010
Surgical treatment of intrahepatic cholangiocarcinoma: outcomes and predictive factors
Ellis M, Cassera M, Vetto J, Orloff S, Hansen P, Billingsley K. Surgical treatment of intrahepatic cholangiocarcinoma: outcomes and predictive factors. Hepato Pancreato Biliary 2010, 13: 59-63. PMID: 21159105, PMCID: PMC3019543, DOI: 10.1111/j.1477-2574.2010.00242.x.Peer-Reviewed Original ResearchConceptsOverall survival rateIntrahepatic cholangiocarcinomaR0 resectionSurgical treatmentR1/R2 resectionResectable intrahepatic cholangiocarcinomaPostoperative liver failureMainstay of treatmentOptimal patient selectionPostoperative complication rateKaplan-Meier methodCox hazard modelPreoperative hypoalbuminaemiaReplete patientsR2 resectionSurgical mortalityComplication rateSurgical resectionSurgical therapyWorse survivalClinicopathologic characteristicsLiver failureOperative detailsPrognostic factorsRecurrence outcomesAdjuvant therapy and survival after resection of pancreatic adenocarcinoma
Mayo S, Austin D, Sheppard B, Mori M, Shipley D, Billingsley K. Adjuvant therapy and survival after resection of pancreatic adenocarcinoma. Cancer 2010, 116: 2932-2940. PMID: 20336787, DOI: 10.1002/cncr.25082.Peer-Reviewed Original ResearchConceptsAdjuvant therapyPancreatic adenocarcinomaOverall survivalAdjuvant treatmentCox proportional hazards modelMedian overall survivalKaplan-Meier methodMedical record reviewPopulation-based cohortOngoing clinical trialsState Cancer RegistryProportional hazards modelPaucity of dataAdjuvant chemoradiationCurative intentR0 resectionMedian survivalPerformance statusComplete resectionRecord reviewCancer RegistryPathologic stageClinical trialsRegistry dataHazards model
2008
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
Whitehead R, Rankin C, Hoff P, Gold P, Billingsley K, Chapman R, Wong L, Ward J, Abbruzzese J, Blanke C. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Investigational New Drugs 2008, 27: 469. PMID: 18941712, PMCID: PMC3024913, DOI: 10.1007/s10637-008-9190-8.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerColorectal cancerPerformance statusSouthwest Oncology Group studyAdequate bone marrowCombination of romidepsinPrior chemotherapy regimenPrior chemotherapy regimensSignificant cardiac diseaseHuman tumor xenograft modelsAdvanced colorectal cancerPhase II trialColorectal cancer patientsGroup of patientsTreatment of patientsTumor growth inhibitionTumor xenograft modelHistone deacetylase inhibitorsEligible patientsPrior chemotherapyPrior regimensStable diseaseAdvanced diseaseChemotherapy regimenChemotherapy regimensSurvival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population
Dobie S, Warren J, Matthews B, Schwartz D, Baldwin L, Billingsley K. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer 2008, 112: 789-799. PMID: 18189291, PMCID: PMC3103394, DOI: 10.1002/cncr.23244.Peer-Reviewed Original ResearchConceptsStage II patientsRectal cancer patientsStage III patientsII patientsCancer patientsStage IIAdjuvant radiationAdjuvant therapyIII patientsGeneral populationStage II rectal cancer patientsLower cancer-related mortalityReceipt of chemoradiationCancer mortality riskCancer-related mortalityMultivariate logistic regressionAdjusted riskAdjuvant chemoradiationChemotherapy receiptSurgical resectionSurvival benefitSEER-MedicareTherapy adherencePatient groupRadiation therapy
2006
Outcome Following Surgical Therapy for Gastrointestinal Stromal Tumors
Gupta M, Sheppard B, Corless C, MacDonell K, Blanke C, Billingsley K. Outcome Following Surgical Therapy for Gastrointestinal Stromal Tumors. Journal Of Gastrointestinal Surgery 2006, 10: 1099-1105. PMID: 16966028, DOI: 10.1016/j.gassur.2006.05.014.Peer-Reviewed Original ResearchConceptsGastrointestinal stromal tumorsMultivisceral resectionStromal tumorsMetastatic diseaseSurgical resectionImatinib mesylateDuodenal gastrointestinal stromal tumorKIT-positive gastrointestinal stromal tumoursCox proportional hazards modelPercent of patientsComplete surgical resectionKaplan-Meier methodLog-rank analysisPresence of metastasesLimits of resectionProportional hazards modelMitotic indexHigh mitotic indexActuarial survivalPostoperative survivalIncomplete resectionSurgical therapyComplete resectionImproved survivalIndependent predictors